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Abstract
Introduction: The incidence of end-stage renal disease is increasing worldwide. Earlier studies reported high prevalence
rates of obesity and hypertension, two major risk factors of chronic kidney disease (CKD), in Golestan Province, Iran. We
aimed to investigate prevalence of moderate to severe CKD and its risk factors in the region.
Methods: Questionnaire data and blood samples were collected from 3591 participants ($18 years old) from the general
population. Based on serum creatinine levels, glomerular filtration rate (GFR) was estimated.
Results: High body mass index (BMI) was common: 35.0% of participants were overweight (BMI 25–29.9) and 24.5% were
obese (BMI $30). Prevalence of CKD stages 3 to 5 (CKD–S3-5), i.e., GFR ,60 mL/min/1.73 m
2, was 4.6%. The odds ratio (OR)
and 95% confidence interval (95% CI) for the risk of CKD–S3-5 associated with every year increase in age was 1.13 (1.11–
1.15). Men were at lower risk of CKD–S3-5 than women (OR=0.28; 95% CI 0.18–0.45). Obesity (OR=1.78; 95% CI 1.04–3.05)
and self-reported diabetes (OR=1.70; 95% CI 1.00–2.86), hypertension (OR=3.16; 95% CI 2.02–4.95), ischemic heart disease
(OR=2.73; 95% CI 1.55–4.81), and myocardial infarction (OR=2.69; 95% CI 1.14–6.32) were associated with increased risk of
CKD–S3-5 in the models adjusted for age and sex. The association persisted for self-reported hypertension even after
adjustments for BMI and history of diabetes (OR=2.85; 95% CI 1.77–4.59).
Conclusion: A considerable proportion of inhabitants in Golestan have CKD–S3-5. Screening of individuals with major risk
factors of CKD, in order to early detection and treatment of impaired renal function, may be plausible. Further studies on
optimal risk prediction of future end-stage renal disease and effectiveness of any screening program are warranted.
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Introduction
Kidney disease contributes to a significant morbidity and
mortality in societies [1]. The incidence of chronic kidney disease
(CKD) and end-stage renal disease (ESRD) is increasing [2,3].
According to the National Health and Nutrition Examination
Surveys (NHANES), while prevalence of CKD (excluding ESRD)
in the United States was 10.0% in 1988–1994, the prevalence
increased to 13.1% in 1999–2004 [4].
In addition to morbidity and common psychosocial outcomes of
the disease, including depression and unemployment, ERSD
patients need dialysis or transplantation facilities, which may place
a big financial burden on the society. In the past decade, 1.1
trillion dollars have been spent for dialysis worldwide [5]. Early
diagnosis and treatment of mild to moderate CKD may prevent or
delay progression of the disease to severer stages [2,3,6,7,8].
Therefore, diagnosis and treatment of CKD in early stages can be
an important public health issue, particularly in the developing
countries with high rates of CKD. Nevertheless, little data on
epidemiology of renal function and abnormalities are available
from many of those countries [9].
Among very few population-based studies on kidney disease in
Iran, a recent large study reported that prevalence of CKD among
individuals .14-years old in different parts of the country was 6%
to 17% [10]. In Golestan Province, northeast of Iran, very high
rates of overweight/obesity and hypertension have recently been
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14216reported among participants in a large-scale cohort study [11]. In
general, CKD is more common in older ages, obese individuals,
and certain medical conditions, including diabetes and hyperten-
sion [12,13,14]. Therefore, Golestan inhabitants might be highly
predisposed to CKD. We conducted a population-based cross-
sectional study in Golestan and collected a wide range of data to
evaluate renal function, based on estimated glomerular filtration
rate (GFR), in the general population and to investigate risk factors
of moderate to severe CKD in the region.
Methods
A pilot trial of the effects of fixed-dose combination therapy
(polypill) on cardiovascular risk factors was conducted recently in
Kalaleh City, Golestan Province [15]. For that study, all men aged
50 to 79 and women aged 55 to 79 years residing in Kalaleh City
were invited to attend initial assessments of their eligibility for the
trial. The number of inhabitant aged 18 years or older in the study
field was 18,218, of which 2427 were in the above specified age
ranges. Excluding those whom we could not contact or were
unable to attend in health center (305 subjects), Questionnaire
data and blood samples were collected from all of those who came
to the study center (Kalaleh Health Center) and agreed to provide
the material (n=1488; participation rate 70%). Eligible individ-
uals were invited to participate in the pilot trial later. Data and
samples from all of the above individuals were used for the current
study, without considering whether or not they were included in
the pilot trial. In order to increase the sample size and study
power, the study participants were contacted by phone and all
individuals aged 18 years or older in their household were invited
to participate in the study. From those who agreed, the same data
and samples as above were obtained. With a participation rate of
over 95% in this group, a total number of 3613 participants were
enrolled in the study from April 2007 to January 2009. A written
informed consent was obtained from all participants. The study
protocol and the informed consent used for this study were
approved by the ethical review committee of Digestive Disease
Research Center of Tehran University of Medical Sciences.
Demographic data and history of medical conditions, including
diabetes mellitus, hypertension, ischemic heart disease, and
myocardial infarction, were collected in face to face interviews
using a structured questionnaire. Weight and height were
measured by interviewers. Systolic and diastolic blood pressures
were obtained twice for both arms during the interviews; only
measurements for right arm were considered for further analyses.
Interviews and physical examinations were conducted by trained
physicians.
Blood samples were drawn after at least 10-hour overnight fast
and were centrifuged within 1 hour of collection. Serum samples
were separated and were kept in 270uC freezers in the study
center for a maximum period of three months. The samples were
transported in dry ice to Endocrinology Research Center of
Tehran University of Medical Sciences, Shariati Hospital, in
Tehran, where serum creatinine and fasting blood sugar were
measured. The duration of transportation was less than 10 hours
and none of the samples were found unfrozen at destination,
where the samples were immediately put in 270uC freezers. The
laboratory analyses were done within a few days after arrival with
endpoint enzymatic photometric method using Hitachi 902 auto-
analyzer. An expert nephrologist attended the Kalaleh Health
Center in a monthly basis and visited the participants who had any
abnormal test. When results of laboratory tests were abnormal,
blood sample collection and tests were repeated approximately
three months later. In this article, we considered a test as abnormal
when it was confirmed in a repeated test. Individuals with
abnormal tests were referred to their family physicians. All family
physicians and internists in the study field had been invited to
attend a lecture by the principal investigator of the study in the
beginning, in which they were told about the study goals and
protocol.
Body mass index (BMI) was categorized according to the World
Health Organization guidelines: ,18.5 (underweight), 18.5–24.9
(normal), 25–29.9 (overweight), and $30 (obese) kg/m
2. Partic-
ipants were classifed as diabetics when they had either self-
reported diabetes (diagnosed by a physician and/or receiving
medications for diabetes) or fasting blood sugar $110 mg/dL.
Hypertension was defined as any of these conditions: (1) self-
reported hypertension (diagnosed by a physician or receiving
medications for hypertension); (2) average systolic blood pressure
$140 mmHg; (3) average diastolic blood pressure $90 mmHg.
To estimate GFR, we used Modification of Diet in Renal
Disease (MDRD) study equation: GFR [mL/min/1.73 m
2]=
1866 (serum creatinine [mg/dL])
-1.156 (age [years])
-0.203 60.742
(if female) 61.212 (if African-American) [16]. We also estimated
GFR using Cockroft-Goult equation [17]: Creatinine Clearance
[ml/min] = ((140 – age [years])/serum creatinine [mg/dL]) x
(weight [kg]/72) 60.85 (if female); the values were standardized
for body surface area calculated using Du Bios Method [18]:
body surface area [m
2] =0.2024760.725 height [m] 60.425
weight [kg]. According to one of the most widely adopted
classifications, proposed by the Kidney Disease Outcomes
Quality Initiative, 5 stages have been defined for CKD [3]. In
stage 1 and stage 2, markers of kidney damage, including
increased urinary excretion of albumin and protein, are present
and glomerular filtration rates (GFR) are $90 and 60–89 mL/
min/1.73 m
2, respectively. Higher stages are defined only by
GFR, which is 30–59, 15–29, and ,15 mL/min/1.73 m
2 in
stages 3, 4, and 5, respectively. In accord with above categories,
we classified the estimated GFR into 5 groups: .90, 60–90, 30–
59, 15–29, and ,15 mL/min/1.73 m
2.
Statistical analysis
We investigated the association between stages 3 to 5 of CKD
(CKD–S3-5) and several factors, including demographic charac-
teristics, BMI, and history of diabetes and hypertension. For this,
individuals with GFR ,60 mL/min/1.73 m
2 were combined and
compared with those having GFR .90 mL/min/1.73 m
2.
Participants with estimated GFR of 60–90 mL/min/1.73 m
2
were not included in these analyses. We calculated crude and
adjusted odds ratios (OR) and 95% confidence intervals (CI) for
the associations in logistic regression models. For diabetes and
hypertension, we investigated the association separately for those
with self-reported disease, those who had abnormal findings in
baseline examinations, and both categories combined. All of the
statistical analyses were done using STATA version 11.
Results
Of 3613 enrolled participants, 22 (0.6%) were excluded because
their laboratory analyses were not completed. Consequently, 3591
individuals were included for further analyses. The number and
mean (standard deviation) age of participants by demographic
characteristics, BMI, and history of medical conditions is shown in
Table 1. Mean (SD) age was 43.8 (15.8) years. Sixty one percent of
participants were women. Many participants had high BMI: 1309
(36.5%) were overweight (BMI =25–29.9 kg/m
2) and 881
(24.5%) were obese (BMI $30 kg/m
2). Diabetes, hypertension,
ischemic heart disease, and myocardial infarction were reported
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Prevalence of diabetes and hypertension, either self-reported or
identified in baseline examinations, was 21.6% and 39.9%,
respectively.
Distribution of MDRD-estimated GFR categories by sex and
age is presented in Table 2. GFR remarkably reduced with age.
For example, the proportion of individuals with GFR 30–59 mL/
min/1.73 m
2 increased from 0.5% among participants below 30
years of age to 20% in those with 70 years of age or more, while
the proportion of individuals with normal GFR in those age
categories were 76% and 10%, respectively. The distribution for
GFRs calculated using Cockroft-Goult is shown in Table S1. The
GFRs based on Cockroft-Goult method were generally lower than
those based on MDRD method. As Cockroft-Goult method may
underestimate the GFR [19], we used only MDRD-based GFRs
for further analyses.
Table 3 shows the association of CKD–S3-5 (MDRD-based
GFR ,60 mL/min/1.73 m
2) with demographic factors, BMI,
and history of diabetes, hypertension, ischemic heart disease, and
myocardial infarction. One hundred sixty seven participants (4.6%
of all participants) had CKD–S3-5. Except for ethnicity, all other
variables in Table 2 showed an association with CKD–S3-5 in
crude analyses. However, after adjustments for age and sex, the
associations for marital status and education level were disap-
peared. The OR (95% CI) for every year increase in age was 1.13
(1.11–1.15) in adjusted models. Men were at lower risk than
women after adjustment for age (OR=0.24; 95% CI 0.16–0.38)
or after extension of the adjustment to BMI and self-reported
diabetes and hypertension (OR=0.28; 95% CI 0.18–0.45).
There was an association between BMI and CKD–S3-5 in
crude analyses. Underweight individuals were at lower risk than
participants with normal BMI (OR=0.21; 95% CI 0.05–0.90),
while overweight (OR=1.86; 95% CI 1.25–2.75) and obese
(OR=2.19; 95% CI 1.54–3.13) participants were at higher risk.
After adjustments for age and sex, the association was attenuated
but was still significant for obese individuals (OR=1.78; 95% CI
1.04–3.05); P value for trend was 0.01. The association for obese
participants disappeared after further adjustment for history of
diabetes.
All categories of diabetes that are shown in Table 3 were
associated with CKD–S3-5 in crude analyses. After adjustment for
age and sex, however, only self-reported diabetes showed an
association (OR=1.70; 95% CI 1.00–2.86). After adjustments for
BMI and other factors, none of the diabetes categories were
associated with CKD–S3-5. Similarly, all groups of hypertension
were associated with CKD–S3-5 in crude analyses. The
association for those who had high blood pressure at the baseline
examinations disappeared in adjusted models. The association for
self-reported hypertension remained after adjustment for age and
sex (OR=3.16; 95% CI 2.02–4.95) or after extension of
adjustments for other factors (OR=2.85; 95% CI 1.77–4.59).
Both ischemic heart disease (OR=2.69; 95% CI 1.14–6.32) and
myocardial infarction (OR=2.73; 95% CI 1.55–4.81) had
significant association with CKD in the models adjusted for age
and sex. The associations became non-significant after further
adjustments for BMI, diabetes, and hypertension.
Discussion
Our study showed that approximately 5% of inhabitants in
Golestan aged 18 years or older had CKD–S3-5, with much
higher rates among the elderly. We found an association between
CKD–S3-5 and BMI and self-reported diabetes and hypertension.
Men were at lower risk of CKD–S3-5 than women. Our study also
showed high prevalence of diabetes mellitus and hypertension in
Golestan.
The prevalence of CKD–S3-5 in our study is similar to the rates
reported by NHANES (1988–1994), which was 4.7% [12], and
Table 1. Distribution of demographic variables, BMI, and





All participants 3591 (100) 43.8 (15.8)
Women 2192 (61.0) 41.2 (15.1)
Men 1399 (39.0) 47.9 (15.9)
Age (years)
,30 847 (23.6) 23.1 (3.5)
30–39 656 (18.3) 34.5 (2.8)
40–49 634 (17.7) 44.4 (3.0)
50–59 806 (22.4) 54.2 (2.9)
60–69 433 (12.0) 63.8 (3.0)
$70 215 (6.0) 72.5 (2.4)
Ethnicity
Sistani 1513 (42.1) 42.4 (15.4)
Turkmen 762 (21.2) 46.6 (15.4)
Fars 864 (24.1) 43.7 (15.9)
Other 452 (12.6) 44.2 (16.6)
Marital Status
Married 2868 (79.9) 46.1 (14.1)
Single 483 (13.4) 23.3 (6.4)
Widow/divorced 240 (6.7) 58.2 (12.4)
Education
No school 1205 (33.5) 57.7 (10.0)
Primary school 732 (20.4) 47.7 (11.8)
Middle school 394 (11.0) 36.9 (11.0)
High school 891 (24.8) 29.3 (10.1)
University 369 (10.3) 33.3 (10.8)
BMI
,18.5 145 (4.0) 34.1 (17.9)
18.5–24.9 1309 (36.5) 40.5 (17.7)
25–29.9 1256 (35.0) 46.5 (14.1)
$30 881 (24.5) 46.5 (12.8)
Diabetes
c
Self-reported 513 (14.3) 45.1 (15.3)
FBS $110 mg/dL 497 (13.8) 54.8 (11.0)
Any criteria 777 (21.6) 48.4 (14.8)
Hypertension
c
Self-reported 736 (20.5) 48.3 (15.7)
Sys $140 or dias $90 mmHg 1073 (29.9) 52.4 (13.2)
Any criteria 1432 (39.9) 49.4 (14.5)
Ischemic heart disease 327 (9.1) 47.6 (16.7)
Myocardial infarction 138 (3.8) 43.1 (15.2)
Abbreviations: BMI, body mass index (kg/m
2); SD, standard deviation.
doi:10.1371/journal.pone.0014216.t001
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studies, even within a country, have reported very different rates
[24]. For example, prevalence of CKD–S3-5 was reported as
18.7% in Japanese general population [25] and as 18.9%, 7.8%,
and 6.5% in 3 other studies from Iran [10,26,27]. This can be
related to true differences in prevalence of the disease in different
populations, variation in the methodology that was used, and
differences in demographic characteristics of study participants,
including age structure. As expected, prevalence of CKD–S3-5
in older ages was higher in this study. This finding is comparable
with results of NHANES study, in which prevalence of
moderately or severely decreased kidney function in age group
over 70 years was 20.6% [12]. Similar to many other developing
regions, the age structure pyramid of the population in Golestan
is highly broad-based, with a large proportion of young people.
Therefore, we expect a rapid increase in the proportion of
elderly people and prevalence of CKD in Golestan within a few
decades.
BMI is associated with CKD [28]. The observed risk associated
with BMI $30 in our study is similar with the risk reported in a
recent Iranian study (1.8-fold increase in risk) [10]. The association
of CKD with BMI may be related to higher prevalence of diabetes
among overweight and obese individuals. The association
disappeared after adjustment for history of diabetes and
hypertension. This suggests that high BMI may be a risk factor
for CKD–S3-5 only when it is associated with chronic disorders.
Diabetes and hypertension are known risk factors for CKD
[12,13,14]. It has been estimated that diabetes and hypertension
are responsible for 40.2% and 24.6% of CKD, respectively, in the
United States [29]. An earlier study in Iran reported 3.8- and 2.6-
fold increased risk of CKD associated with diabetes and
hypertension, respectively [10]. The risk associated with self-
reported diabetes and hypertension in our study was 1.7-fold and
3.2-fold, respectively. Individuals that were found to have diabetes
and hypertension only in baseline examinations were at lower risk
compared to those with self-reported disease. It is very likely that
the first group had subtle or recently-onset disease. Therefore,
their disease might not have enough severity or duration to
significantly influence the kidney function. This may explain the
difference observed in the association of CKD with self-reported
and accidentally-found diabetes and hypertension in our study. As
expected, the association of CKD with diabetes and hypertension
was attenuated after adjustment for BMI, which is strongly
correlated with diabetes and is one of the risk factors of
hypertension.
The observed prevalence of diabetes in our population (21.6%)
is higher than the world prevalence of diabetes among adults (aged
20–79 years), which is estimated to be 6.4% in 2010 [30]. The
reported prevalence rates for diabetes and hypertension in other
areas of Iran varies considerably. Among studies on CKD in Iran,
the reported prevalence in three studies was 9.2%, 13.7%, and
29.0% for diabetes and 9.9%, 25.8%, and 17.4% for hypertension
[10,26,27]. However, in a recent national surveillance on
approximately 30,000 Iranians aged 15–64 years, prevalence of
diabetes and hypertension was reported as 17.4% and 3.5%,
respectively [31]. A part of difference in prevalence rates may be
related to variations in the demographic structure of studied
populations; because, for example, diabetes and hypertension are
more common in the elderly and in urban than rural dwellers
[32,33]. In our study, selection bias cannot also be ruled out;
individuals with health problems, including diabetes and hyper-
tension, might have been keener to participate in the study.
Prevalence of diabetes and hypertension in Golestan may be
estimated more accurately in future within the Golestan Cohort
Study; a recent large-scale prospective study with approximately
50,000 participants, which was basically designed to study
gastrointestinal cancers [34,35].
In our study, women were at higher risk of CKD than men.
Such an association has been reported in several other studies
[24,26,27,36]. An earlier study in Golestan reported much higher
BMI among women than in men. However, after adjustments for
BMI, women were still at higher risk of CKD. There is no clear
explanation for this association. However, it may partly be related
to residual confounding from BMI and sub-clinical diabetes.
Further studies are warranted in this regard.
Fairly large number of participants and collection of data on
several factors and medical conditions that enabled us to adjust
our results for several potential confounding factors are main
strengths of our study. On the other hand, estimating GFR from
serum creatinine level has well-recognized limitations, including
substantial variation in creatinine production by age, sex, and race
[37]. To minimize the impact of these limitations we used MDRD
equation, which seems to have higher precision to estimate GFR
compared to other methods that are based on serum creatinine
Table 2. MDRD-based Glomerular filtration rate by sex and age.
Mean age
(SD), years Total no. GFR $90 GFR: 60–89 GFR: 30–59 GFR: 15–29 GFR ,15
All participants 43.8 (15.8) 3591 1240 (34.5) 2186 (60.9) 154 (4.3) 6 (0.2) 5 (0.1)
Women 41.2 (15.1) 2192 721 (32.9) 1367 (62.4) 99 (4.5) 4 (0.2) 1 (0.1)
Men 48.0 (15.9) 1399 519 (37.1) 819 (58.5) 55 (3.9) 2 (0.1) 4 (0.3)
Age (years)
,30 23.1 (3.5) 847 647 (76.4) 194 (22.9) 4 (0.5) 1 (0.1) 1 (0.1)
30–39 34.5 (2.8) 656 186 (28.3) 465 (70.9) 5 (0.8) 0 (0.0) 0 (0.0)
40–49 44.4 (3.0) 634 117 (18.4) 502 (79.2) 14 (2.2) 1 (0.2) 0 (0.0)
50–59 54.2 (2.9) 806 184 (22.8) 593 (73.6) 26 (3.2) 2 (0.3) 1 (0.1)
60–69 63.8 (3.0) 433 84 (19.4) 284 (65.6) 62 (14.3) 2 (0.5) 1 (0.2)
$70 72.5 (2.4) 215 22 (10.2) 148 (68.8) 43 (20.0) 0 (0.0) 2 (0.9)
Abbreviations: BMI, body mass index (kg/m
2); GFR, glomerular filtration rate (ml/min/1.73 m
2); MDRD, Modification of Diet in Renal Disease; SD, standard deviation.
Values are numbers (percentages) of participants unless stated otherwise.
doi:10.1371/journal.pone.0014216.t002
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calibrated against the values of the laboratory in which data for the
development of MDRD equation were generated [38]. Selection
bias might have happened in the first call of participants, but not
in the second call, which had a high participation rate. The bias
might have influenced the reported prevalence rates of disorders,
including CKD–S3-5, diabetes, and hypertension. However, it is
unlikely that the bias distorted the association between CKD–S3-5
and its risk factors.
In conclusion, aging and high prevalence of obesity, diabetes,
and hypertension in Golestan are alarming signs that indicate the
need for preventive measures in the region. These may include
early diagnosis and treatment of CKD and elimination or control
of its risk factors; e.g., programs for weight control and early
















Age, year (continuous) - - 1.12 (1.10–1.14) 1.13 (1.11–1.15) 1.13 (1.11–1.15)
Sex
Women 721 (58.2) 104 (63.0) Reference Reference Reference
Men 519 (41.8) 61 (37.0) 0.81 (0.58–1.14) 0.24 (0.16–0.38) 0.28 (0.18–0.45)
Ethnicity
Sistani 516 (41.6) 58 (35.2) Reference Reference Reference
Turkmen 254 (20.5) 40 (24.2) 1.40 (0.91–2.15) 0.96 (0.56–1.64) 0.83 (0.47–1.45)
Fars 301 (24.3) 42 (25.5) 1.24 (0.81–1.89) 0.99 (0.58–1.68) 0.78 (0.44–1.38)
Other 169 (13.6) 25 (15.1) 1.32 (0.80–2.17) 1.01 (0.54–1.90) 0.72 (0.37–1.40)
Marital Status
Married 845 (68.2) 130 (78.8) Reference Reference Reference
Single 354 (28.5) 2 (1.2) 0.04 (0.01–0.15) 0.42 (0.08–2.12) 0.52 (0.10–2.65)
Widow/divorced 41 (3.3) 33 (20.0) 5.23 (3.19–8.58) 0.80 (0.42–1.53) 0.75 (0.39–1.47)
Education
No school 238 (13.2) 114 (69.1) Reference Reference Reference
Primary school 171 (13.8) 29 (17.6) 0.35 (0.23–0.57) 1.37 (0.78–2.41) 1.22 (0.68–2.18)
Middle school 150 (12.1) 8 (4.8) 0.11 (0.05–0.23) 1.79 (0.70–2.56) 1.58 (0.61–4.05)
High school 514 (41.4) 10 (6.1) 0.04 (0.02–0.08) 1.56 (0.61–3.94) 1.48 (0.57–3.83)
University 167 (13.5) 4 (2.4) 0.05 (0.02–0.14) 1.63 (0.49–5.40) 1.43 (0.43–4.80)
BMI
,18.5 100 (48.0) 2 (33.3) 0.21 (0.05–0.90) 0.44 (0.09–2.13) 0.46 (0.08–2.20)
18.5–24.9 595 (8.0) 55 (1.2) Reference Reference Reference
25–29.9 338 (27.3) 58 (35.2) 1.86 (1.25–2.75) 1.55 (0.93–2.57) 1.57 (0.78–2.19)
$30 207 (19.7) 50 (30.3) 2.61 (1.73–3.95) 1.78 (1.04–3.05) 1.35 (0.77–2.36)
P for trend ,0.001 0.01 0.15
Diabetes
c
Self-reported 161 (13.0) 32 (19.4) 1.61 (1.06–2.45) 1.70 (1.00–2.86) 1.13 (0.65–1.98)
FBS $110 mg/dL 116 (9.4) 43 (26.1) 3.42 (2.30–5.08) 1.24 (0.76–2.00) 0.94 (0.56–1.57)
Any criteria 225 (18.2) 54 (32.7) 2.19 (1.54–3.13) 1.47 (0.94–2.30) 1.07 (0.66–1.72)
Hypertension
c
Self-reported 182 (14.7) 71 (43.0) 4.39 (3.11–6.21) 3.16 (2.02–4.95) 2.85 (1.77–4.59)
Sys $140 or dias $90 mmHg 243 (19.6) 83 (50.3) 4.15 (2.97–5.81) 1.43 (0.93–2.18) 1.26 (0.81–1.94)
Any criteria 356 (28.7) 100 (60.6) 3.80 (2.71–5.33) 2.64 (1.50–2.78) 1.61 (1.04–2.50)
IHD
c 87 (7.0) 39 (23.6) 4.10 (2.70–6.24) 2.73 (1.55–4.81) 1.73 (0.93–3.21)
MI
c 47 (3.8) 13 (7.9) 2.17 (1.15–4.10) 2.69 (1.14–6.32) 1.55 (0.61–3.92)
Abbreviations: BMI, body mass index (kg/m
2); CI, confidence interval; CKD, chronic kidney disease; dias, diastolic blood pressure; FBS, fasting blood sugar; GFR,
glomerular filtration rate (ml/min/1.73 m
2); IHD, ischemic heart disease; MI, myocardial infarction; OR, odds ratio; sys, systolic blood pressure.
aAdjusted for sex and age (categorical variable). Sex variable was only adjusted for age and vice versa.
bAdjusted for sex, age (categorical variable, as Table 1), and BMI (categorical variable), self-reported diabetes mellitus, and self-reported hypertension. When one of
these possible confounders was the variable of interest, the adjustments were made for the other possible confounders. None of the diabetes and hypertension
variables were adjusted for self-reported diabetes and self-reported hypertension, respectively.
cThe reference groups included those who did not have the respective condition.
doi:10.1371/journal.pone.0014216.t003
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preventive measures can also be beneficial for several common
chronic diseases, including cardiovascular disease. Further studies
in the region are required to explain the higher risk observed
among women, role of some other risk factors, including insulin
resistance and metabolic syndrome [39], and prevalence and risk
factors of mild CKD, for which markers of kidney damage, such as
albuminuria, should be examined. Screening for CKD in the
general population may not be feasible or cost-effective, but it may
be considered for those with certain risk factors of CKD [40],
including diabetes and hypertension, particularly among the
elderly and women. Golestan Cohort Study may provide
invaluable material to investigate risk factors of CKD prospectively
and to optimal risk prediction of future ERSD in the region.
Supporting Information
Table S1 Glomerular filtration rate (calculated using Cockroft-
Goult method) by demographic characteristics and BMI. Values
are numbers (percentages) of participants unless stated otherwise.
Found at: doi:10.1371/journal.pone.0014216.s001 (0.04 MB
DOC)
Author Contributions
Conceived and designed the experiments: IN RS FM RS MYG BB ANH
BL RM. Performed the experiments: IN RS FM RS MYG BB ANH BL
RM. Analyzed the data: FI RS MYG MH. Contributed reagents/
materials/analysis tools: IN FA FI RS FM RS MH RM. Wrote the paper:
IN FA FI RS MH BB ANH BL RM.
References
1. Minino AM, Smith BL (2001) Deaths: preliminary data for 2000. Natl Vital Stat
Rep 49: 1–40.
2. Eknoyan G, Levey AS, Levin NW, Keane WF (2001) The national epidemic of
chronic kidney disease. What we know and what we can do. Postgrad Med 110:
23–29: quiz 28.
3. Goolsby MJ (2002) National Kidney Foundation Guidelines for chronic kidney
disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 14:
238–242.
4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of
chronic kidney disease in the United States. JAMA 298: 2038–2047.
5. Lysaght MJ (2002) Maintenance dialysis population dynamics: current trends
and long-term implications. J Am Soc Nephrol 13(Suppl 1): S37–40.
6. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, et al. (2001)
Prevalence of high blood pressure and elevated serum creatinine level in the
United States: findings from the third National Health and Nutrition
Examination Survey (1988-1994). Arch Intern Med 161: 1207–1216.
7. McClellan WM, Knight DF, Karp H, Brown WW (1997) Early detection and
treatment of renal disease in hospitalized diabetic and hypertensive patients:
important differences between practice and published guidelines. Am J Kidney
Dis 29: 368–375.
8. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, et al. (2001)
Management of patients with chronic renal insufficiency in the Northeastern
United States. J Am Soc Nephrol 12: 1501–1507.
9. BarsoumRS(2006)Chronickidneydiseaseinthedevelopingworld.NEnglJMed
354: 997–999.
10. Safarinejad MR (2009) The epidemiology of adult chronic kidney disease in a
population-based study in Iran: prevalence and associated risk factors. J Nephrol
22: 99–108.
11. Bahrami H, Sadatsafavi M, Pourshams A, Kamangar F, Nouraei M, et al. (2006)
Obesity and hypertension in an Iranian cohort study; Iranian women experience
higher rates of obesity and hypertension than American women. BMC Public
Health 6: 158.
12. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of
chronic kidney disease and decreased kidney function in the adult US
population: Third National Health and Nutrition Examination Survey.
Am J Kidney Dis 41: 1–12.
13. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, et al. (2003) Early
detection of kidney disease in community settings: the Kidney Early Evaluation
Program (KEEP). Am J Kidney Dis 42: 22–35.
14. Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, et al. (2005) Prevalence of
decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int 68:
2837–2845.
15. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, et al. (2010) A
pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose
combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract
64: 1220–1227.
16. Brosnahan G, Fraer M (2010) Chronic kidney disease: whom to screen and how
to treat, part 1: definition, epidemiology, and laboratory testing. South Med J
103: 140–146.
17. Cockroft D, Gault M (1976) Prediction of creatinine clearance from serum
creatinine. Nephron 16: 11.
18. Dubios D, Dubios E (1916) A formula to estimate the approximate area if height
and weight be known. Annals of Internal Medicine 17: 9.
19. Itoh K (2003) Comparison of methods for determination of glomerular filtration
rate: Tc-99m-DTPA renography, predicted creatinine clearance method and
plasma sample method. Ann Nucl Med 17: 561–565.
20. Ramirez SP, McClellan W, Port FK, Hsu SI (2002) Risk factors for proteinuria
in a large, multiracial, southeast Asian population. J Am Soc Nephrol 13:
1907–1917.
21. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, et al. (2003)
Prevalence of kidney damage in Australian adults: The AusDiab kidney study.
J Am Soc Nephrol 14: S131–138.
22. Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, et al. (2008) Prevalence and factors
associated with CKD: a population study from Beijing. Am J Kidney Dis 51:
373–384.
23. Varma PP, Raman DK, Ramakrishnan TS, Singh P, Varma A (2010)
Prevalence of early stages of chronic kidney disease in apparently healthy
central government employees in India. Nephrol Dial Transplant.
24. Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in
population-based studies: systematic review. BMC Public Health 8: 117.
25. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, et al. (2007) Prevalence of
chronic kidney disease (CKD) in the Japanese general population predicted by
the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11:
156–163.
26. Hosseinpanah F, Kasraei F, Nassiri AA, Azizi F (2009) High prevalence of
chronic kidney disease in Iran: a large population-based study. BMC Public
Health 9: 44.
27. Mahdavi-Mazdeh M, Saeed Hashemi Nazri S, Hajghasemi E, Nozari B, Zinat
Nadia H, et al. Screening for decreased renal function in taxi drivers in Tehran,
Iran. Ren Fail 32: 62–68.
28. Nomura I, Kato J, Kitamura K (2009) Association between body mass index and
chronic kidney disease: a population-based, cross-sectional study of a Japanese
community. Vasc Health Risk Manag 5: 315–320.
29. CDC (2007) 29 Prevalence of chronic kidney disease and associated risk factors–
United States, 1999-2004. MMWR Morb Mortal Wkly Rep 56: 161–165.
30. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of
diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4–14.
31. Ebrahimi M, Mansournia MA, Haghdoost AA, Abazari A, Alaeddini F, et al.
(2010) Social disparities in prevalence, treatment and control of hypertension in
Iran: second National Surveillance of Risk Factors of Noncommunicable
Diseases, 2006. J Hypertens 28: 1620–1629.
32. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, et al. (2000)
Hypertension and stroke in Asia: prevalence, control and strategies in developing
countries for prevention. J Hum Hypertens 14: 749–763.
33. Chambers JC, Kooner JS (2002) Diabetes, insulin resistance and vascular disease
among Indian Asians and Europeans. Semin Vasc Med 2: 199–214.
34. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, et al. (2009)
Tea drinking habits and oesophageal cancer in a high risk area in northern Iran:
population based case-control study. BMJ 338: b929.
35. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, et al. (2010)
Cohort Profile: The Golestan Cohort Study–a prospective study of oesophageal
cancer in northern Iran. Int J Epidemiol 39: 52–59.
36. Ong-Ajyooth L, Vareesangthip K, Khonputsa P, Aekplakorn W (2009)
Prevalence of chronic kidney disease in Thai adults: a national health survey.
BMC Nephrol 10: 35.
37. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal
function: new insights into old concepts. Clin Chem 38: 1933–1953.
38. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, et al. (2002) Calibration
and random variation of the serum creatinine assay as critical elements of using
equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920–929.
39. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Pirulli A, et al. (2010) Metabolic
syndrome and chronic kidney disease. J Ren Nutr 20: S19–23.
40. Hallan SI, Stevens P (2010) Screening for chronic kidney disease: which
strategy? J Nephrol 23: 147–155.
Chronic Kidney Disease in Iran
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14216